… the 10-year cost utility of afatinib versus gefitinib. Only direct … cost was considered, including
first-line treatment cost, management cost of adverse events, subsequent therapy costs after …

… Deterministic sensitivity analyses showed that utility in PF had the highest impact on model
outcomes for both arms. When the afatinib arm utility in PF varied from 0.66 to 0.72, the …

… PC], gefitinib, erlotinib, and afatinib) among … Costs in the Chinese setting were estimated
by using local hospital data and literatures. A 5% annual discount rate was applied to both costs …

… QALY gained at additional cost by afatinib versus gefitinib in China [22]. … cost-effectiveness
analyses in China that the afatinib strategy gained higher QALYs than chemotherapy, gefitinib …

… A net benefit regression (NBR) framework was used to assess the comparative cost
effectiveness of afatinib, erlotinib, and gefitinib [46]. We estimated the net benefit value for the ith …

… guidelines, to assess the cost-utility of gefitinib, erlotinib and afatinib. The model was based
… cost-utility ratio (ICUR) per quality-adjusted life-year (QALY) gained and incremental cost-…

… afatinib therapy was superior to erlotinib and gefitinib as first-line therapy for NSCLC that is
EGFR (+). However, afatinib … A prospective cost-utility pharmacoeconomic study regarding …

… cost-effectiveness of erlotinib, gefitinib, afatinib … price of gefitinib, cost of BSC, and utility
values. However, none of these parameters’ fluctuation led to the ICER of gefitinib versus afatinib …

… Utilities were taken from METEOR. Costs data were specific to Scotland and list prices from
the British National Formulary were used for drugs for this analysis. RESULTS: In the base …

… The utility of PFS and the cost of afatinib had the most important impact on … price of afatinib
and the cost of genetic screening. While several pharmacoeconomic analyses reveal gefitinib …